Citations

Institution: Mayo Clinic Clear

Showing 10 of 108152 citations.

Abstract 4117085: Frequency and Patterns of Paroxysmal Supraventricular Tachycardia Episodes Among Patients Opting For Acute Drug Treatment: Analysis of the NODE-303 Open-Label Etripamil Trial
Hu, Derek , Parody, Maria Lenor, Rafii, Farhad, Stambler, Bruce S. , Shardonofsky, Silvia, Bharucha, David B. , Camm, A. John, Desai, Nihar R. , Ip, James E. , Noseworthy, Peter A. , Pokorney, Sean D. , Singh, Narendra

Circulation | November 13, 2024 | Volume: 150 | Issue: Suppl_1 | Pages: No page available

10.1161/circ.150.suppl_1.4117085 Get It

Background: Etripamil nasal spray (NS) is a fast acting, self-administered calcium channel blocker in development for the termination of AV-nodal-dependent supraventricular tachycardia (SVT). Prior randomized, placebo-controlled and open-label studies have demonstrated favorable safety and efficacy of etripamil in converting paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm (SR) self-administered without direct medical supervision. Research Question/Hypothesis: To assess patterns and annualized PSVT episode frequency among patients opting to self-administer acute treatment with etripamil. Methods: NODE-303 was an event-driven, multi-center, open-label Phase 3 study, conducted in North and South America to evaluate the safety and efficacy of etripamil in patients with documented PSVT over multiple episodes. Test dosing was not performed prior to at-home use. Enrolled patients, upon perceiving symptoms of PSVT: applied an ambulatory ECG monitor, performed a previously trained vagal maneuver and, if symptoms persisted, self-administered etripamil NS 70 mg. During the study, the protocol was amended to allow a repeat dose (70 mg) if symptoms persisted 10 min after the first dose. Each patient could self-treat up to 4 episodes. Results: Of 1,116 enrolled patients, 503 (45.1%) treated ≥1 perceived PSVT episode (safety population). Etripamil achieved conversion to SR in 60% of patients by 30 minutes and 70% by 60 minutes. A total of 220, 118, 62, and 103 patients completed the study with 1, 2, 3, and 4 etripamil-treated perceived episodes of PSVT, respectively, with an average time on study of 440 days. Among these patients, the average number of annualized etripamil-treated PSVT episodes was 3.2 (standard deviation 3.8). Annualized use: etripamil was self-administered for 0-2 PSVT episodes per year, 2-6 episodes, 6-12 episodes, and >12 episodes, in 54%, 32%, 10%, and 4% of patients, respectively (Figure). Conclusions: This analysis aimed to assess the annualized use of etripamil NS in a real-world setting, by analyzing how often patients would self-administer the drug for PSVT episodes. Of patients that self-administered etripamil (n=503), the majority treated >1 episode and the annualized frequency of episodes treated with etripamil was 3.2 episodes/yr.
Abstract 4114970: Comparing efficacy and safety between pulsed field ablation, cryoballoon ablation and high-power short duration radiofrequency ablation in atrial fibrillation: A systematic review and Network meta-analysis.
Deepan, Natee , Sripusanapan, Adivitch , Tokavanich, Nithi , Prasitlumkum, Narut , Siranart, Noppachai , Chokesuwattanaskul, Ronpichai , Navaravong, Leenhapong , Kewcharoen, Jakrin , Pajareya, Patavee

Circulation | November 13, 2024 | Volume: 150 | Issue: Suppl_1 | Pages: No page available

10.1161/circ.150.suppl_1.4114970 Get It

Background: Pulsed field ablation (PFA) and high-power short-duration radiofrequency ablation (HPSD) are emerging techniques for treating atrial fibrillation (AF), offering promising results compared to cryoballoon ablation (CBA). This network meta-analysis aims to evaluates the efficacy and safety of PFA, HPSD, and CBA. Method: PubMed, Embase, Cochrane Central Register of Controlled Trials, and EBSCO Information Services were systematically searched for relevant studies until April 2024. The primary outcome is freedom from atrial arrhythmia. A random-effects model was used for data synthesis, and P-scores were employed for outcome ranking. Point estimation (odd ratios) was calculated for comparisons. Results: Fifteen studies were included in our network meta-analysis, involving 5,093 atrial fibrillation patients: 812 (16%), 2,659 (52%), and 1,622 (32%) patients underwent PFA, CBA, and HPSD, respectively. PFA demonstrated the highest efficacy (P-scores 99.3%). Point estimation between PFA and HPSD, and PFA and CBA, were 1.394 (95% CI: 1.047-1.858) and 1.479 (95% CI: 1.134–1.929), respectively. PFA had higher complications compared to HPSD (OR=4.44, 95% CI: 1.405-14.031) and CBA (OR=2.581, 95% CI: 0.992–6.720). HPSD had the shortest fluoroscopic time (P-scores 100%), while CBA had the longest (P-scores 0%). PFA had the shortest procedural time compared to CBA and HPSD with P-scores of 100% 50% and 0%, respectively. Conclusion: PFA showed higher efficacy but higher complication risk than HPSD and CBA. HPSD and CBA demonstrated similar efficacy and safety.
Next‐generation biomarkers for alcohol consumption and alcohol use disorder diagnosis, prognosis, and treatment: A critical review
Clark, Shaunna L. , Hartwell, Emily E. , Choi, Doo‐Sup , Krystal, John H. , Messing, Robert O. , Ferguson, Laura B. , Choi, Doo-Sup

Alcohol, Clinical and Experimental Research | November 13, 2024 | Volume: 49 | Issue: 1 | Pages: 5-24

10.1111/acer.15476 | PMID 39532676 Get It

AbstractThis critical review summarizes the current state of omics‐based biomarkers in the alcohol research field. We first provide definitions and background information on alcohol and alcohol use disorder (AUD), biomarkers, and “omic” technologies. We next summarize using (1) genetic information as risk/prognostic biomarkers for the onset of alcohol‐related problems and the progression from regular drinking to problematic drinking (including AUD), (2) epigenetic information as diagnostic biomarkers for AUD and risk biomarkers for alcohol consumption, (3) transcriptomic information as diagnostic biomarkers for AUD, risk biomarkers for alcohol consumption, and (4) metabolomic information as diagnostic biomarkers for AUD, risk biomarkers for alcohol consumption, and predictive biomarkers for response to acamprosate in subjects with AUD. In the final section, the clinical implications of the findings are discussed, and recommendations are made for future research.
Initial Proof‐of‐Concept Study on Immediate Effects of External Advanced Pneumatic Compression on Pharyngeal and Laryngeal Internal Lymphedema Using a Fluoroscopic Measurement Tool
Gregor, Jessica W. , Keole, Nandita , McGary, Alyssa , Patel, Samir H. , Chang, Brent, Chang, Brent A. , Gregor, Jessica W

Head & Neck | November 13, 2024 | Volume: 47 | Issue: 3 | Pages: 962-973

10.1002/hed.27983 | PMID 39533783 Get It

ABSTRACTBackgroundExternal and internal head and neck cancer related lymphedema (HNCRL) is a common consequence of radiation treatment (RT). Currently, internal HNCRL can be clinically assessed endoscopically using a visuoperceptual, ordinal rating scale. Use of fluoroscopy to identify and measure internal HNCRL has been explored but is not widely used in clinical practice. Advanced Pneumatic Compression (APC) has shown external HNCRL reduction after a single treatment, whereas internal HNCRL reduction has not yet been assessed.MethodsFluoroscopic lateral scouts and TIMS Review software (TIMS Medical) were used to assess immediate internal HNCRL measures of 30 HNC patients with RT history following a single APC treatment. Pre and post external measures were also obtained. Paired t‐test was used to assess changes in pre and post measures. A post‐treatment survey was completed.ResultsAll 30 patients had both immediate external and internal HNCRL reductions, and all reductions were statistically significant. All reported positive benefit.ConclusionsA single, external APC treatment immediately impacted the extent of pharyngeal and laryngeal edema in post‐radiated HNC survivors. Fluoroscopy can be a clinically useful and complementary modality to detect, surveil, and measure internal HNCRL.
My First Foley
Li, Oscar , Lee, Yeonsoo Sara , Sara Lee, Yeonsoo

Academic Medicine | November 13, 2024 | Volume: 100 | Issue: 2 | Pages: 152-152

10.1097/acm.0000000000005921 | PMID 39878518 Get It

Pathologic dural invasion is associated with regional recurrence in olfactory neuroblastoma: A multi‐institutional study
Tang, Anthony , Fung, Nicholas , Champagne, Pierre‐Olivier , Fernandez‐Miranda, Juan C. , Gardner, Paul , Hwang, Peter H. , Nayak, Jayakar V. , Patel, Chirag , Patel, Zara M. , Celda, María Peris, Sanusi, Olabisi , Thorp, Brian D. , Zenonos, Georgios A. , Zwagerman, Nathan T. , Nayak, Jayakar V , Patel, Zara , Pinheiro-Neto, Carlos, Snyderman, Carl H , Wang, Eric W , Choby, Garret , Hwang, Peter H , Taori, Suchet , Fung, Nicholas, Almeida, João Paulo , Pinheiro‐Neto, Carlos , Gompel, Jamie J. Van , Geltzeiler, Mathew , Choby, Garret

International Forum of Allergy & Rhinology | November 13, 2024 | Volume: 15 | Issue: 4 | Pages: 373-383

10.1002/alr.23489 | PMID 39535364 Get It

AbstractObjectiveNeck metastases are a poor prognostic factor in olfactory neuroblastoma (ONB). Pathologic dural invasion (pathDI) may increase the risk of neck metastases due to invasion of dural lymphatics. We aim to evaluate the prognostic value of pathDI in predicting rates of neck metastases and recurrence using a large, multicenter database of ONB patients.Data sourcesRetrospective review of a prospective, multicenter database of electronic health records of all patients who presented with ONB between 2005 and 2021 at nine tertiary academic care centers within North America.Review methodsClinicopathologic features including modified Kadish staging systems, margin status, treatment modalities, Hyams grading, follow‐up time, and survival.ResultsOf 258 ONB patients, 189 patients met the inclusion criteria. The 10‐year neck recurrence‐free survival (neck‐RFS) rates were 85.7% (75.6‒97.3) and 61.8% (47.9‒79.8) for patients without and with pathDI, respectively (p = 0.018). Time‐to‐event multivariable regression analysis found pathDI to have an odds ratios of 9.7 (95% confidence interval [CI] 1.2–80.4, p = 0.04) for neck‐RFS and 9.5 for RFS at any site (95% CI 1.1–83.3, p = 0.04).ConclusionIn multivariable analysis, the presence of pathDI appears to be the strongest predictor of neck recurrence and recurrence at any site. Future studies exploring the benefit of elective neck dissection or radiation for patients with pathDI may impact disease management.
Methotrexate and cytarabine in adult LCH: High risk, high reward and maintenance free?
Abeykoon, Jithma P. , Go, Ronald S. , Azoulay, Lévi-Dan , Haroche, Julien, Go, Ronald S , Haroche, Julien

British Journal of Haematology | November 13, 2024 | Volume: 206 | Issue: 2 | Pages: 792-794

10.1111/bjh.19903 | PMID 39535303 Get It

Lin et al. report the long‐term follow‐up of a phase II trial involving 95 adult patients with Langerhans cell histiocytosis (LCH), investigating the combination of methotrexate and cytarabine (MA). After a median follow‐up of 6.5 years, the study showed high response rates, with 90% overall response; 55% of patients free from an event such as disease progression, poor response or death; and 93% of patients were alive, though nearly half experienced febrile neutropenia. This prospective study helps fill gaps in understanding adult LCH treatment, indicating that fixed‐duration chemotherapy can yield durable responses despite its associated risks. It emphasizes the importance of personalized treatment decisions, considering both fixed‐duration chemotherapy and continuous targeted agents based on patient and disease‐specific factors.Commentary on: Lin et al. Long term follow‐up of methotrexate and cytarabine in adult patients with Langerhans cell histiocytosis. Br J Haematol 2025; 206:576‐584.
Shaping the Future of Infectious Diseases: The Journey to Promote Value, Opportunity, and Positive Messaging
Paras, Molly L , Chirch, Lisa M , Aziz, Mariam, Balba, Gayle , Benson, Constance A. , Butt, Saira , James, Scott H. , McCarty, Todd P , Razonable, Raymund R. , Reece, Rebecca , Shnekendorf, Rachel, Viehman, J Alex, acknowledgments), For the Infectious Diseases Society of America Fellowship Training Program Directors Community of Practice and Working Group (complete list of contributing authors in the Working Group listed in, Abdoler, Emily , Acharya, Kartikey, Angarone, Michael , Babik, Jennifer M. , Bartash, Rachel , Bhanot, Nitin , Blackburn, Brian G. , Blyth, Dana M , Bran, Andres, Burke, Victoria, Carey, A., Cheney, Leonard, Chow, Brian , Clough, Lisa , Sanctis, Jorgelina T. de, George, Ige A, Goebel, Melanie , Goshorn, Eli S, Gutiérrez, Ramiro L. , Herc, Erica , Hillenbrand, Molly , Khalil, Sarwat, Lebron, Dora, Lee, Mikyung , Leuck, Anne‐Marie , Gil, Raul Macias , Mapa, Christopher, Matt, Brionna, Maziarz, Eileen K , Melia, Michael T. , Mitra, Subhashis , Monday, Lea , Montague, Brian T. , Murphy, Holly A, Novick, Elizabeth E, Nnedu, Obinna, Ongunti, Sharon, Osorio, Georgina, Pepe, Rosalie, Perez, Federico, Pilkington, Edward F., Raybould, Jillian E. , Reid, Gail , Robinson, Sara , Sanchez, Martha , Schultz, Sara , Sellers, Christopher J., Simon, Matthew , Sisco, Lauren, Slosar-Cheah, Magdalena, Sobhanie, Mohammad Mahdee , Stead, Wendy , Theodore, Deborah , Wald‐Dickler, Noah , Weber, Devin , Witherspoon, Kelsey, Yabes, Joseph , Zuckerman, Richard A. , McCarty, T P , Benson, Constance , Razonable, Raymund R , Swartz, Talia H , Luther, Vera P , Pérez, Federico , Swartz, Talia H. , Luther, Vera , acknowledgments), For the Infectious Diseases Society of America Fellowship Training Program Directors Community of Practice and Working Group (complete list of contributing authors in the Working Group listed in, Blumberg, Emily A. , Bourque, Daniel L. , Burke, Victoria, Carey, Adrienne L, Cunha, Cheston B. , Dobrzynski, David , George, Ige Abraham , Kaltsas, Anna , Khalil, Sarwat, Kiley, John L , Marcos, Luis A. , Murphy, Holly A, Nori, Priya , Robinson, Sara, Sisco, Lauren , Stapleton, Ann E. , Streit, Judy A. , Weisenberg, Scott A.

Open Forum Infectious Diseases | November 13, 2024 | Volume: 11 | Issue: 12 | Pages: No page available

10.1093/ofid/ofae669 | PMID 39610405 Get It

Abstract The field of infectious diseases (ID) offers a rewarding career path and is widely viewed as an essential subspecialty in medicine. However, in recent years, these positive aspects have been overshadowed by concerns surrounding low fellowship match rates, undercompensation, and burnout. The Infectious Diseases Society of America Fellowship Training Program Directors Committee met in 2023, discussed the future of ID as a specialty, and sought to develop strategies to highlight the value and opportunities of ID for future generations, as well as underscore the importance of and provide tools for positive messaging to trainees about the subspecialty. This paper presents ideas generated at this meeting and is meant to serve as a reference for ID training program directors, as well as the wider ID community, in uplifting and shaping the future of the field.
Prevention and Treatment of Cancer-Related Infections, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology
Baden, Lindsey R. , Almyroudis, Nikolaos G. , Angarone, Michael , Baluch, Aliyah , Barros, Nicolas , Buss, Brian, Cohen, Stuart H. , Cooper, Brenda , Chiang, Augusto Dulanto , Boghdadly, Zeinab El , Gregg, Kevin , Hakim, Hana , Ho, Dora Y. , Lee, Rachael , Lee, Francesca , Logan, Cathy , Manley, Kristen, Pisano, Jennifer , Saullo, Jennifer L. , Schuster, Mindy G. , Seo, Susan K. , Taplitz, Randy , Topal, Jeffrey , Wilson, John , Zimmer, Andrea , Cassara, Carly J., Diwan, Zeenat, Swaminathan, Sankar , Khawaja, Fareed , Multani, Ashrit , Pande, Anupam , Pergam, Steven A. , Shoham, Shmuel , Kumar, Rashmi

Journal of the National Comprehensive Cancer Network | November 13, 2024 | Volume: 22 | Issue: 9 | Pages: 617-644

10.6004/jnccn.2024.0056 | PMID 39536464 Get It

There is an increased risk of infection in patients with cancer that results in higher morbidity and mortality. Several risk factors can predispose these patients to infectious complications. Some such factors include immunocompromised states like neutropenia, allogeneic hematopoietic cell transplantation, and graft-versus-host disease, while others include immunosuppressive agents like corticosteroids, purine analogs, monoclonal antibodies, and other emerging cancer therapeutics like CAR T-cell therapy. The NCCN Guidelines for the Prevention and Treatment of Cancer-Related Infections address infection concerns that may be observed in these immunocompromised populations and characterize the major pathogens to which patients with cancer are susceptible, with a focus on the prevention, diagnosis, and treatment of major common and opportunistic infections. This paper highlights 2 recently updated sections of the guidelines, namely, infection concerns related to CAR T-cell therapy and antimicrobial prophylaxis recommendations, including vaccination, in patients at high-risk for infections.
NCCN Guidelines® Insights: Management of Immunotherapy-Related Toxicities, Version 2.2024
Thompson, John A. , Schneider, Bryan J. , Brahmer, Julie R. , Zaid, Mohammad Abu , Achufusi, Amaka, Armand, Philippe , Bermas, Bonnie L. , Braaten, Tawnie , Chokshi, Saurin , Crees, Zachary , Davies, Marianne, Deng, Changchun , Gesthalter, Yaron , Jallouk, Andrew , Khalil, Maya, Marr, Alissa , McGettigan, Suzanne , Medina, Theresa , Mohindra, Nisha , Patel, Sandip Pravin , Prosek, Jason, Reddy, Sunil , Reid, Pankti , Ryder, Mabel , Shofer, Scott , Sosman, Jeffrey A. , Zucker, Stephen D. , Lyons, Megan , Hang, Lisa, Ryder, Mabel , Berkenstock, Meghan , Bermas, Bonnie , Budde, Lihua E. , Jain, Michael D. , Jain, Prantesh , Kaffenberger, B , Lechner, Melissa G , Li, Tianhong , McPherson, Jordan P. , Medina, Theresa Michelle , Olszanski, Anthony J. , Oluwole, Olalekan O. , Ryan, John, Salman, Huda , Santomasso, Bianca , Wang, Yinghong , Zaha, Vlad G , Awotiwon, Ajibola

Journal of the National Comprehensive Cancer Network | November 13, 2024 | Volume: 22 | Issue: 9 | Pages: 582-592

10.6004/jnccn.2024.0057 | PMID 39536465 Get It

The NCCN Guidelines for the Management of Immunotherapy-Related Toxicities are intended to provide oncology practitioners with guidance on how to manage the wide-ranging and potentially fatal toxicities that may occur with cancer immunotherapy. The guidelines address immune-related adverse events related to immune checkpoint inhibitors, CAR T-cell therapies, and lymphocyte engagers (which include T-cell–engaging bispecific antibodies). These NCCN Guidelines Insights highlight recent guideline updates pertaining to the management of emerging toxicities related to cancer immunotherapy.